Skip to content
Screener

STERIS STE Noncontrolling interests in subsidiaries

Noncontrolling interests in subsidiaries at other companies

Baxter International logo
Baxter InternationalBAX
-$27M0.0%
Boston Scientific logo
Boston ScientificBSX
$240M+3.0%
Fortive logo
FortiveFTV
$8.8M+23.9%
Charles River Laboratories logo
Charles River LaboratoriesCRL
$6.35M+0.7%
Tenet Healthcare logo
Tenet HealthcareTHC
$1.9B+10.0%
GE HealthCare Technologies logo
GE HealthCare TechnologiesGEHC
$14M-33.3%

Other financials

Income statement

See full
Revenue$1.5B+7.3%
Gross profit$684.1M+8.9%
Operating income$285.8M+16.2%
Net income$200.1M+12.8%
EPS (diluted)$2.04+14.0%

Balance sheet

See full
Cash & equivalents$482.3M+72.4%
Total debt$1.9B-0.5%
Total equity$7.2B+3.6%
Total assets$10.7B+3.2%

Cash flow

See full
Operating cash flow$367.1M-12.6%
CapEx$87.5M-6.5%
Free cash flow$279.6M-14.3%

Valuation

See full
Market cap$23.14B-2.7%
Enterprise value$24.59B-3.4%
P/E28.8×-8.1×
P/S3.8×-0.4×

Profitability

See full
Gross margin44.4%+0.3pp
Operating margin18.9%+2.3pp
Net margin13.3%+1.7pp
FCF margin15.3%-1.0pp

Returns & leverage

See full
Return on equity11.4%+1.7pp
Debt / equity0.3×0.0×
Current ratio1.9×-0.3×

Where this comes from

Reported directly by STERIS in its filing.

Tagged under the XBRL concept us-gaap:MinorityInterest.

The source filing: STERIS’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 4:06 PM EDT
Fiscal quarter
Q1 FY2027
Calendar quarter
Q2 2026
Accession
0001628280-26-054830
Line itemJune 30,2026March 31,2026
Commitments and contingencies (see Note 9)
Ordinary shares, with $0.001 par value; 500.0 shares authorized; 97.5 and 97.8 ordinary shares issued and outstanding, respectively4,179.54,280.9
Retained earnings3,154.53,015.9
Accumulated other comprehensive loss(127.3)(113.1)
Total shareholders’ equity7,206.77,183.6
Noncontrolling interests14.513.6
Total equity7,221.37,197.2
Total liabilities and equity$10,736.1$10,737.2

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is STERIS's noncontrolling interests in subsidiaries?
STERIS (STE) reported noncontrolling interests in subsidiaries of $14.5M in Q2 2026.
How has STERIS's noncontrolling interests in subsidiaries changed year-over-year?
STERIS's noncontrolling interests in subsidiaries increased by 12.4% year-over-year, from $12.9M to $14.5M.
What is the long-term trend for STERIS's noncontrolling interests in subsidiaries?
Over 5 years (2021 to 2026), STERIS's noncontrolling interests in subsidiaries has grown at a 5.4% compound annual growth rate (CAGR), from $10.48M to $13.6M.
What does noncontrolling interests in subsidiaries mean?
This represents the portion of a subsidiary's net assets that is owned by outside shareholders rather than the parent company. It is reported within equity to show the total value of the subsidiary's assets and liabilities that are not attributable to the parent. It reflects the non-controlling stake in consolidated entities.

Ask your AI about STERIS's noncontrolling interests in subsidiaries.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude